<DOC>
	<DOCNO>NCT01266018</DOCNO>
	<brief_summary>This open-label , phase II study ADI-PEG 20 subject relapse SCLC . ADI-PEG 20 administer intramuscularly ( IM ) fix dose 320 IU/m2 weekly 4-week cycle . The primary objective assessment clinical efficacy primary endpoint tumor response RECIST 4 week . Secondary objective assessment safety , pharmacodynamics , immunogenicity ADI-PEG 20 , well , clinical efficacy secondary endpoint overall survival .</brief_summary>
	<brief_title>Study ADI-PEG 20 Patients With Relapsed Sensitive Refractory Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<criteria>1 . Patients must histologically document small cell lung cancer ( SCLC ) 2 . Cohort 1 : `` Sensitive '' disease patient one previous line chemotherapy maintain appropriate response 90 day Cohort 2 : `` refractory '' disease patient , one previous line chemotherapy either response progress less 90 day complete treatment patient ( `` sensitive '' `` refractory '' ) need 3rd line therapy , i.e. , complete fail two previous line chemotherapy 3 . Measurable disease use RECIST criterion 4 . ASS tumor expression must either negative &lt; 5 % + tumor cell ( IHC analysis ) 5 . ECOG performance score 0 2 6 . Laboratory parameter vital function normal range . Laboratory abnormality clinically significant generally permit , except follow laboratory parameter , must within range specify : Neutrophil count ≥ 1.5 x 109/L Lymphocyte count ≥ 0.5 x 109/L Platelet count ≥ 50 x 109/L Serum creatinine ≤ 1.5 ULN ( CrCl ≥ 60mL/min ) Serum bilirubin ≤ 2mg/dL ( ≤ 34 µmol/L ) Serum uric acid ≤ 8mg/dL ( ≤ 0.48 mmol/L ) INR ≤ 1.5 Partial thromboplastin time ≤ 1.5 x ULN 7 . Age ≥ 18 year 8 . Able willing give valid write informed consent 1 . Subjects previously treat ADIPEG 20 2 . Known allergy pegylated product . 3 . History uncontrolled seizure . 4 . Serious illness , e.g . serious infection require antibiotic , bleed disorder , condition opinion Investigator would interfere ability patient fulfill study requirement . 5 . Metastatic disease central nervous system , unless treat stable . 6 . Known immunodeficiency HIV positivity . 7 . Participation clinical trial involve another investigational agent within 3 week prior first dose study agent . 8 . Any malignancy require concomitant therapy restrict accord Section 5.3 . 9 . Mental impairment may compromise ability give informed consent comply requirement study . 10 . Lack availability clinical followup assessment . 11 . Pregnancy breast feed . 12 . Refusal inability use effective mean contraception men woman childbearing potential duration study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>small cell lung cancer</keyword>
	<keyword>SCLC</keyword>
	<keyword>ADI-PEG 20</keyword>
	<keyword>arginine deiminase pegylated</keyword>
</DOC>